The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.